Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02207114 · ClinicalTrials.gov registry record · NA

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

A NA study of Sepsis, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
145
Enrollment target
1
Study location

NCT02207114 is a NA study of Sepsis that has completed, run by University of Pennsylvania. The registered enrollment target is 145 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02207114, a NA study of Sepsis, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
145 participants
Enrollment target
1
Study location

Study Summary

The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.

Conditions Studied

Interventions

  • OTHER Biomarker Algorithm Intervention

Study Locations (1)

Pennsylvania

  • Hospital of the University of Pennsylvania - Medical Intensive Care Unit - Philadelphia

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2012-01
Est. Completion 2023-12
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02207114

The ClinicalTrials.gov registry entry for NCT02207114 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Biomarker Algorithm Intervention is the first listed.

NCT02207114 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02207114 about?

NCT02207114 is a clinical study titled "Using Biomarkers to Optimize Antibiotic Strategies in Sepsis". The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the resu...

What is the current status of trial NCT02207114?

This trial is currently completed. It is a NA study. The enrollment target is 145 participants. The study started on 2012-01. Estimated completion is 2023-12.

What conditions does trial NCT02207114 study?

This clinical trial studies the following conditions: Sepsis.

What interventions are being tested in trial NCT02207114?

The interventions under investigation include: Biomarker Algorithm Intervention (OTHER).

Who is sponsoring clinical trial NCT02207114?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02207114 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.